【中慧生物(02627.HK)2025 年中期业绩报告：商业化加速兑现 研发管线梯次突破】智通财经APP获悉，8月28日，江苏中慧元通生物科技股份有限公司（以下简称：中慧生物；股票代码：02627）发布了其上市后的首份中期业绩公告。财报显示，公司核心产品四价流感病毒亚单位疫苗——慧尔康欣 ®商业化成效显著，营收实现跨越式增长，期内亏损同比收窄，同时研发管线按计划推进，全球化布局逐步落地。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.